Development of a novel beta-glucan supplemented hydrogel spray
formulation and wound healing efficacy in a db/db diabetic mouse model by Grip, Jostein et al.
European Journal of Pharmaceutics and Biopharmaceutics 169 (2021) 280–291
Available online 30 October 2021
0939-6411/© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Development of a novel beta-glucan supplemented hydrogel spray 
formulation and wound healing efficacy in a db/db diabetic mouse model 
Jostein Grip a,b, Erik Steene a, Rolf Einar Engstad a, Jeff Hart c, Andrea Bell c, Ingrid Skjæveland a, 
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A B S T R A C T   
To relieve the severe economic and social burdens and patient suffering caused by the increasing incidence of 
chronic wounds, more effective treatments are urgently needed. In this study, we focused on developing a novel 
sprayable wound dressing with the active ingredient β-1,3/1,6-glucan (βG). Since βG is already available as the 
active ingredient in a commercial wound healing product provided as a hydrogel in a tube (βG-Gel), the 
sprayable format should bring clinical benefit by being easily sprayed onto wounds; whilst retaining βG-Gel’s 
physical stability, biological safety and wound healing efficacy. Potentially sprayable βG hydrogels were 
therefore formulated, based on an experimental design setup. One spray formulation, named βG-Spray, was 
selected for further investigation, as it showed favorable rheological and spraying properties. The βG-Spray was 
furthermore found to be stable at room temperature for more than a year, retaining its rheological properties and 
sprayability. The cytotoxicity of βG-Spray in keratinocytes in vitro, was shown to be promising even at the highest 
tested concentration of 100 μg/ml. The βG-Spray also displayed favorable fluid affinity characteristics, with a 
capacity to both donate and absorb close to 10% fluid relative to its own weight. Finally, the βG-Spray was 
proven comparably effective to the commercial product, βG-Gel, and superior to both the water and the carrier 
controls (NoβG-Spray), in terms of its ability to promote wound healing in healing-impaired animals. Contraction 
was found to be the main wound closure mechanism responsible for the improvement seen in the βG-treatment 
groups (βG-Spray and βG-Gel). In conclusion, the novel sprayable βG formulation, confirmed its potential to 
expand the clinical use of βG as wound dressing.   
1. Introduction 
The impact of chronic wounds on society is immense [1,2], as 
chronic wounds are severely lowering the many patients quality of life 
[3–5]. With both an aging population, and the prevalence of diabetes 
expected to rise dramatically in the coming years [6], the prevalence of 
chronic wounds in general, and diabetic foot ulcers in particular, are 
expected to rise. Knowing that there is approximately a one-third chance 
that people having diabetics also develop foot ulcers [7], and that 
chronic wounds already represent the largest contributor to the annual 
cost of wound treatment [2], it is essential that cost-efficient therapies 
for chronic wounds are developed [8–10]. The wound healing process 
involves various cell types and signalling molecules that sequentially 
coordinate the different phases of the wound repair processes, namely: 
hemostasis, inflammation, proliferation and remodelling. In chronic 
wounds, the healing process stalls in the inflammatory phase, which has 
been attributed to a range of pathophysiological defects, including 
impaired macrophage function [11,12]. Understanding the underlying 
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pathology and healing status of a wound is important in selecting the 
most appropriate wound dressing, as there is no universally effective 
wound product [13]. Academia and industry are now focusing more on 
developing advanced and active wound healing products, by developing 
specialized products for different wound-types [5]. Advanced wound 
dressings can either influence the healing processes directly, or indi-
rectly, by the release of bioactive substances within the wound [14–17]. 
β-glucans are carbohydrate polymers that are found in the cell walls 
of many organisms, including yeast, fungi and certain bacteria. 
Throughout evolution, the mammalian immune system has learned to 
identify these structures as Pathogen Associated Molecular Patterns 
(PAMPs), and this enable β-glucans to induce immune modulatory ef-
fects in humans [18–22]. β-glucans have been shown to revert immuno- 
compromised macrophages back to a functioning phenotype in humans, 
an effect that may explain the benefit of β-glucan as an active ingredient 
in the treatment of chronic wounds [23–27]. Another reported benefit of 
β-glucans is their ability to modulate the wound healing process, and 
reduce scarring in mice, which may prove beneficial to patients with 
excessive and disfiguring scarring [28]. 
β-1,3/1,6-glucan (βG) from baker’s yeast (Saccharomyces cerevisiae), 
has previously been proven to have favorable effects on wound healing, 
both in the format of electrospun nanofibers [27] , and as a hydrogel 
[23]. At present, commercially available βG-products for chronic wound 
treatments are formulated as semisolid hydrogels (e.g. Woulgan®, Bio-
tec BetaGlucans AS, Norway), applied to the wound with a gloved finger. 
Hydrogels are moisture retentive products that are recommended for use 
on dry to low exuding deep chronic wounds, and are known to alleviate 
chronic wound pain. 
Based on the reported therapeutic advantages of spray administra-
tion for topical wound treatments, this method of application may be an 
appropriate method by which to deliver βG to chronic wounds [29–31]. 
Spray administration is a simple, non-contact method, which permits 
quick and easy application/re-application of liquid/semi-solid formu-
lations to wounds [32]. The non-contact nature of spray administration 
makes it particularly attractive for the treatment of painful wounds. But, 
since we failed in a previous attempt to prepare a sprayable wound 
dressing with βG as the active ingredient, due to adverse effect seen for 
the formulations during in vivo testing in mice [33], an alternative and 
more effective βG-Spray formulations was targeted. Since these previ-
ously detected adverse effects were found to be related to the applied 
thickening agent, Carbopol, we aimed to develop a sprayable βG- 
formulation using, instead of Carbopol, a medium viscosity carbox-
ymethyl cellulose (CMC) as a thickening agent, and glycerol as a hu-
mectant. Both CMC and glycerol are extensively used in wound healing 
products and have well-documented effects on wound healing 
[5,34–36]. Our reference formulation, βG-Gel (comprised of 2.0 % βG w/ 
v, a high viscosity CMC and glycerol), is a commercially available wound 
healing product, with well documented effects in chronic wounds of 
different etiology [26,37]. The composition of this non-sprayable 
reference formulation thus also encourage to apply CMC and glycerol 
in the development of the novel βG sprayable formulation. 
In this study, the rheological properties of the spray formulation (βG- 
Spray) and a carrier control spray (NoβG-Spray), including stability and 
sprayability were initially established. Secondly, toxicity to immortal-
ized human keratinocytes and fluid affinity were investigated and 
compared to the well-characterised commercially available β-glucan 
hydrogel (βG-Gel). Finally, the spray formulation, βG-Spray, was eval-
uated in terms of its impact on the healing of full-thickness excisional 
wounds in the healing-impaired db/db mouse model, together with 
NoβG-Spray and βG-Gel, for comparison, and water and growth factors 
(PDGF-BB and TGF-α), as negative and positive control, respectively. 
2. Materials and methods 
2.1. Materials 
Glycerol (1,2,3-propanetriol) was purchased from VWR (Fontenay 
sous Bois, France). Milli-Q water was produced using a Direct 8 Water 
Purification System by Merck Millipore (Billerica, MA, USA). Soluble 
β-1,3/1,6-glucan (βG; 2.5 % w/w) and Woulgan® Gel (βG-Gel) were 
gifted by Biotec Betaglucans AS (Tromsø, Norway). Sodium carbox-
ymethyl cellulose (CMC) 7M1F (MW 250,000) was purchased from 
Ashland (Wilmington, DE, USA). Gelatin from porcine skin was obtained 
from Sigma-Aldrich (Taufkirchen, Germany) and Acto™ Agar was pur-
chased from BD (Le Pont de Claix, France). The HaCaT cell line 
(immortalized human keratinocytes) was purchased from Thermo Fisher 
Scientific (Waltham, USA). RPMI growth medium was obtained from 
Sigma Aldrich (Steinheim, Germany). The MTT cell proliferation kit 
assay was purchased from Roche (Sigma Aldrich). The rh-platelet- 
derived growth factor-BB (PDGF-BB) and rh-transforming growth fac-
tor-α (TGF-α) were purchased from PeproTech EC Ltd (London, UK). 
Isoflurane (IsoFlo®) was from Zoetis (London, UK), and Buprenorphine 
(Vetergesic®) was purchased from Alstoe Animal Health (Espoo, 
Finland). 10 % Neutral Buffered Formalin, Haematoxylin and Eosin 
were purchased from Sigma. Picrosirius red solution was purchased 
from Pioneer Research Chemicals (UK). 
2.2. Preparation of the spray formulations 
The formulations were prepared from four ingredients; CMC, glyc-
erol and water, and the active ingredient βG. βG was provided as a sterile 
hydrogel with 2.5 % (w/w) soluble β-1,3/1,6-glucan dispersed in water, 
prepared by a patented method [38]. This βG-hydrogel can be liquefied 
by heating, and contains soluble βG with a MW of around 7 × 105 g/mol. 
The first step of the preparation was to disperse and wet CMC in glycerol, 
before further dispersion in Milli-Q water followed by addition of pre-
heated (50 ◦C) βG 2.5 % (w/w) . All of the respective ingredients were 
adjusted to reach the aimed concentrations. The composition variables/ 
weight ratio applied for the different ingredients are given in the Sup-
plementary Table S1. All ingredients were thoroughly mixed using an 
Ultra-Turrax (T25, IKA®-Werke GmbH & Co. KG, Germany). The for-
mulations were autoclaved at 121 ◦C for 20 min and allowed to swell for 
a minimum of one week at room temperature, before further testing. For 
the initial spray test, 15 formulations were prepared, with concentra-
tions of βG ranging from 1.6 to 2.4 % (w/w), CMC from 0.5 to 2.5 % (w/ 
w) and glycerol from zero to 20 % (w/w). The design matrix was ob-
tained by Design-Expert® software (version 10.0.8.0) from Stat-Ease, 
Inc. (Minneapolis, MN. USA). The design was a full two-level factorial 
design with 3 factors (23 = 8 combinations) with four center points. The 
factorial points were replicated to give a total of 20 runs representing 
eight different formulations. The design was augmented with an addi-
tional block of axial star points and two additional center points to make 
a central composite design, giving a total of 34 runs representing 15 
different formulations [39]. 
2.3. Sprayability 
Spraying characteristics were tested using two versions of an airless 
spray nozzle Comfort®-actuator (Ursatec Verpackung GmbH, Germany) 
delivering either 45 or 140 µL per dose, attached to a 10 mL 
polypropylene-container. The run order was randomly conducted, 
assorted by Design-Expert® to exclude bias. The actuators were placed 
10 cm from a horizontal oriented sheet of paper, pressed and the 
sprayability recorded based on the observation made. 
2.4. Rheological assessments 
The rheological properties of the 15 different formulations, including 
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the selected βG containing spray formulation (βG-Spray), a carrier 
control (NoβG-Spray) and a marketed βG gel (βG-Gel), were investigated 
using a Discovery HR-2 Hybrid Rheometer (TA Instruments, New Castle, 
DE, USA), equipped with Peltier plate temperature control and a 40 mm 
parallel plate geometry. Samples were carefully loaded on to the Peltier 
plate using a spoon to prevent any “pre-shear”. The geometry was 
lowered to a gap of 1050 µm (trim gap), excess gel was removed, and the 
plate lowered to a 1000 µm gap (geometry gap). A “temperature soak 
step” of minimum 1 min at 25 ◦C was included prior to all measure-
ments. An “oscillation time sweep protocol” and an “oscillation ampli-
tude sweep protocol” were run in succession on each sample. The 
“oscillation time sweep protocol” was used to measure the elastic 
modulus (G′), viscous modulus (G′′) and phase angle (δ; tanδ = G’’G’ ) of 
the unbroken gel (measured within the linear viscoelastic range), while 
the “oscillation amplitude sweep protocol” was used to determine the 
yield stress. The yield stress equals the oscillation stress required to 
“break” the gel, defined here as the modulus crossover (G′′= G′) when 
the formulation loses its elastic dominant properties. The “oscillation 
time sweep protocol” was carried out using a displacement of 0.001 rad 
at 1.0 Hz over 60 s, while the “oscillation amplitude sweep protocol” 
used a torque increment per step of 100 µN‧m from 100 to 10 000 µN‧m 
with an oscillation frequency of 1 Hz. An “oscillation temperature ramp 
protocol” was used to measure the melting (gel-to-sol) temperatures of 
the formulations. For the temperature ramps, the geometry was also 
fitted with a solvent trap to prevent moisture from evaporating. This 
protocol was run with a displacement of 0.001 rad at 1.0 Hz with the 
following temperature program: 180 s at 25 ◦C; 1.0 ◦C/min ramp up to 
55 ◦C. The melting temperature (gel-to-sol) was defined as the temper-
ature of modulus crossover in the increasing temperature ramp. 
2.5. Stability 
In order to test the stability of the formulations selected for the in vivo 
experiment (βG-Spray and NoβG-Spray), the “oscillation time sweep 
protocol” and “oscillation amplitude sweep protocol” were applied as 
previously described. The formulations were stored at room tempera-
ture, and measurements conducted after 1, 2, 6, 14, 26 and 56 weeks 
storage. All results were processed using the Trios software v. 3.2.0.3877 
(TA Instruments, New Castle, DE, USA). 
2.6. Fluid affinity 
Fluid absorption and donation were tested according to the EU in-
dustry standard EN 13726–1:2002, as previously reported by our group 
[33,40]. We used a simulated wound exudate (Solution A), emulating 
the ion concentration of human serum or wound exudate (142 mmol 
Na+, 2.5 mmol Ca2+). First, 60 mL syringes (B. Braun Melsungen, Hes-
sen, Germany) with the tip removed, were filled with 10.0 ± 0.1 g 
gelatin or the same amount of agar solution. Thereafter, the syringes 
were covered with Parafilm® and left to settle for 3 h at 25 ± 2 ◦C. After 
removing the Parafilm®, the total weight (W1) of the syringe with its 
content was recorded. Thereafter, 10.0 ± 0.1 g of test formulation was 
added to the syringe and the total mass (W2) (corresponding to W1 + test 
formulation), was recorded. The syringe was then again covered with 
Parafilm® and incubated at 25 ± 2 ◦C for 48 h. After incubation, the 
Parafilm® was removed and the mass was recorded (W3) before 
removing the test formulation. Finally, the mass of the syringe with 
either the formulation-exposed agar or gelatin (W4) was recorded. The 
fluid donation or absorption (% w/w) of the formulation (W5) was 
calculated using the equation (Eq. (1), below), also described in the EU 
industry standard EN 13726–1:2002 [40]. Five replicate experiments 
were performed on each formulation. 
W5 =
(
(W3 − W4) − (W2 − W1)
(W2 − W1)
)
x100% (1)  
2.7. Cytotoxicity of spray formulations 
The cytotoxicity of the spray formulations was tested in vitro using 
human keratinocytes (HaCaT cells), as reported previously by our group 
[27]. In short, the cells (1 × 105 cells/mL) were cultured in flat bottomed 
96 well plates containing 90 µL/well of culture medium supplemented 
with 10 µL of growth media (for control) or media containing test 
samples to give final exposure concentrations of 1, 10 or 100 μg/mL. 
After incubation for 24 h, 10 μL of MTT was added to all wells, and the 
plates incubated for a further 4 h. After adding 100 μL of a solubilizing 
reagent, the cells were incubated for another 24 h. An ELISA plate reader 
was used to detect the 580 nm UV absorption of soluble formazan. The 
UV absorption for the control group was used to normalize the data, 
with the control set to be 100 % viable. The effects of the test samples at 
various concentration on cell toxicity were expressed as mean percent-
age viability of two independent experiments for each sample. Control 
samples were tested in quadruplicate. 
2.8. Effect of spray formulations on wound healing in diabetic mice 
In vivo evaluation of the wound healing potential of the formulations 
was undertaken in the healing-impaired db/db diabetic mouse model, 
according to the methods previously described by our group [27,33]. 
The experiment was conducted in accordance with the specific re-
quirements of diabetic animals and in agreement with UK Home Office 
regulations [41]. Nine- to ten-week-old male db/db diabetic mice (BKS. 
Cg-m Dock7m +/+ Leprdb /J mice) purchased from Jackson Labs (Bar 
Harbor, ME, USA), were allowed to acclimate in the animal facility for 
one week prior to the start of the study. Fifty animals (weight 45.3 ± 2.8 
g) were randomly allocated to five groups (10 mice per group): i) pos-
itive control (10 µg rh-platelet-derived growth factor-BB [PDGF-BB] and 
1 µg rh-transforming growth factor-α [TGF-α] (PeproTech EC Ltd, Lon-
don, UK) in 0.5 % w/v HPMC (Sigma, UK); ii) βG-Gel (commercial 
product), iii) βG-Spray, iv) NoβG-Spray (vehicle control) and, v) nega-
tive control (sterile water for injection). 
Full-thickness, 10 × 10 mm square wounds were created approxi-
mately 10 mm from the spine on the left mid dorsal flank using straight 
iris scissors. The area was shaved, cleaned with 4 % chlorhexidine and 
swabbed with 70 % EtOH before wounding, and covered with Bio-
clusive® film dressing (Systagenix Wound Management, Gargrave, UK) 
immediately after wounding. Treatment formulations were injected 
through the film dressing (into the wound) using a 27-gauge needle. The 
administered dose was 50 µL for all treatments. The three test formu-
lations and the negative control (water) were applied on post-wounding 
days 0, 2, 4, 6 and 8; whereas the positive control was applied on post- 
wounding days 0, 1, 2, 3, 4, 5 and 6 (detailed description in Supple-
mentary Table S2, in Appendix 1). 
Anesthetisia was induced using 4 % isoflurane/air (IsoFlo®, Zoetis, 
London, UK) and maintained with 2 % isoflurane. Analgesia, in the form 
of Buprenorphine (Vetergesic®, Alstoe Animal Health, Espoo, Finland), 
was administered (75 µg/kg, s.c.) to reduce discomfort immediately 
after wounding, and subsequently according to clinical need. 
2.8.1. Macroscopic assessment of wound healing 
The “open wound area” (AGT) and the “extent of contraction” (CGT) 
of each wound were measured (using Image Pro Plus image analysis 
software - version 4.1.0.0, Media Cybernetics, Rockville, MD, USA) from 
calibrated digital wound photographs (Fig. 1) taken on post-wounding 
days 0, 4, 8, 12, 16, 20 and 24. The “original wound area” (A0) was 
10 × 10 mm. “Percentage wound closure” over time (relative to the 
original wound area), and the contribution of “wound contraction” and 
“wound re-epithelialization” to “wound closure”, were derived from 
these measures (according to Equations (2), 3 and 4, below). 
(Eq. (2)) “Percentage wound area remaining”: The open wound area 
remaining at a given time point relative to the original wound area. 
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(Eq. (3)) “Percentage wound contraction”: The difference between 
the contracted wound area at a given time point and the original wound 






(Eq. (4)) “Percentage re-epithelialization”: The contracted wound 
area at a given time minus the open wound area at that given time, as a 





x100% (4)  
2.8.2. Histologic assessment of wound healing 
Skin samples, containing the wound with surrounding normal skin, 
were harvested from four animals in each treatment group on post- 
wounding day 24. These tissue samples were fixed (10 % Neutral Buff-
ered Formalin, Sigma) and processed to paraffin wax. Sections (6 µm), 
taken through the center of each wound, were stained with: i) Haema-
toxylin & Eosin (H&E) and ii) the collagen-specific stain Picrosirius Red 
[42]. The stained sections were then digitally scanned (at x20 equivalent 
magnification) using an Aperio AT2 whole slide scanner (Leica Bio-
systems, Germany). “Granulation tissue depth” and the “extent of wound 
re-epithelialization” were measured from digital scans of H&E-stained 
sections using Aperio Imagescope software (version 12.3.0.5056, Leica 
Biosystems, Germany). “Granulation tissue depth” (d) was measured at 
nine equally-spaced points across each wound and a mean depth 
calculated for each wound. The “amount of new epithelium” extending 
from the two wound edges (A and B, Fig. 2)), was expressed as a per-
centage of the full length of the wound (A + B + C). “Granulation tissue 
depth” and “% re-epithelialization” (calculated as described in Eq. (5) 
were compared between treatment groups. 
(Eq. (5)) Percentage re-epithelialization: 
(
A + B
A + B + C
)
x100% (5) 
“Collagen deposition” within wound tissues was quantified from 
Picrosirius Red-stained sections. Digital scans were viewed using Image- 
J software (NIH, USA) and three regions of interest; left margin, central 
wound and right margin (each 1000 × 1000 μm) were identified. Each 
region of interest was then extracted and viewed using Image Pro Plus 
software (Fig. 3A and 3B), and images manipulated (using a pre-set 
threshold) to exclude all non-collagenous structures (Fig. 3C). The 
area within each region of interest “occupied by collagen” (i.e., red 
Fig. 1. Illustration of the wound healing parameters and terminology used to assess the progress of wound closure during the study. A) A wound on day 0 (day of 
surgery), B) The same wound on post-wounding day 12. 
Fig. 2. Post-wounding day 24 diabetic mouse wound section stained with haematoxylin and eosin (H&E) showing: “re-epithelialization from the wound margins” (A 
& B), a “central non-epithelialized region” (C), and “granulation tissue depth” (d) at nine points across the wound. 
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staining) was measured and expressed as a percentage of the whole re-
gion of interest (i.e., 1 mm2). The “collagen content” of the two outer 
(wound marginal) regions of interest was averaged, and “collagen 
deposition” with the central and marginal regions was compared be-
tween treatment groups. 
2.9. Statistical analysis 
For stability and the fluid affinity data, outliers were removed using 
maximum normed residual test [43]. For the stability study, a two-tailed 
t-test was used to determine the difference between time points, and p- 
values < 0.05 were considered significant. In the in vivo study, the two 
sample non-parametric statistical test Mann-Whitney U test was used to 
test for statistically significant differences between groups, with a sig-
nificance level of 5 % (p < 0.05). 
Fig. 3. A) Diabetic mouse wound section (day 24) stained specifically for collagen using with Picrosirius Red, with 3 (1000 × 1000 μm) sub-regions shown (bar 500 
μm); B) enlarged right-marginal region - dark red staining is mature collagen (bar 100 μm); C) Image B manipulated to display collagen staining only (bar 100 μm). 
Table 1 
Rheological characteristics of the β-glucan containing formulations. All measurements are an average of two independent experiments except for the center points 
(±SD).  
Formulation no    Oscillation time sweep Oscillation amplitude sweep Oscillation temp. ramp  
βG conc. CMC conc. Glycerol conc. Phase angle, δ Yield stress Melting point (gel-to-sol)  
% (w/w) % (w/w) % (w/w) (degree) (Pa) (◦C) 
1 1.6 1.5 10 9.17 (±0.6) 44.0 (±0.9) 38.9 (±0.4) 
2 1.8 1.0 5.0 6.75 (±1.6) 29.6 (±5.0) 38.6 (±0.1) 
3 1.8 1.0 15 6.70 (±0.4) 30.2 (±5.6) 42.6 (±0.0) 
4 1.8 2.0 5.0 10.8 (±0.1) 52.2 (±3.3) 37.8 (±0.1) 
5 1.8 2.0 15 9.95 (±0.4) 68.4 (±1.3) 41.7 (±0.1) 
6 2.0 0.5 10 5.57 (±0.1) 31.5 (±4.7) 40.9 (±0.6) 
7 2.0 1.5 0.0 9.61 (±0.9) 39.4 (±6.2) 34.6 (±0.4) 
8d 2.0 1.5 10 7.08 (±1.2) 62.5 (±7.5) 40.7 (±0.7) 
9 2.0 1.5 20 6.17 (±0.4) 93.7 (±3.3) 44.2 (±1.3) 
10/βG-Spraya 2.0 2.5 10 10.3 (±0.0) 93.5 (±5.5) 39.8 (±0.1) 
11 2.2 1.0 5.0 5.50 (±0.1) 41.2 (±1.1) 39.6 (±0.4) 
12 2.2 1.0 15 5.20 (±0.1) 57.2 (±8.3) 44.2 (±0.2) 
13 2.2 2.0 5.0 8.60 (±0.3) 75.2 (±3.0) 39.1 (±0.3) 
14 2.2 2.0 15 8.85 (±2.1) 97.2 (±9.6) 43.1 (±0.3) 
15 2.4 1.5 10 5.74 (±0.4) 89.6 (±1.5) 42.1 (±0.0) 
βG-Gelb 2.0 1.8c 20 30.56 (±0.6) 172.09 (±4.2) 40.1 (±0.2)  
a The selected spray formulation. 
b The commercial product. 
c High MW CMC (All other formulations contained Medium MW CMC). 
d Center point; n = 6. 
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3. Results 
3.1. Sprayability and rheological assessments, including stability 
The nozzle Comfort® spray system from Ursatec Verpackung GmbH, 
Germany, was selected for the study. It is produced for multiple use 
without the need for preservatives, as an inner bag collapses as the 
container empties (Fig. S1, Appendix 1). Actuators giving both 45 and 
140 µL per dose were tested. All the tested βG-containing spray formu-
lations (Table 1) were sprayable with both actuators, and the formula-
tions were spread on an area of approx. 5 cm ø at a distance of 10 cm 
from the actuator. 
The results from the rheological measurements, including the 
respective formulations‘ phase angle, yield stress and melting point (gel- 
to-sol) , are summarized in Table 1. 
All formulations were confirmed to be hydrogels (Table 1), as the 
phase angle was below 45◦ [44]. The melting temperature, determined 
from the “oscillation temperature ramp protocol”, was 39.8 ◦C (SD ±
0.1) and 40.1 ◦C (SD ± 0.2), for the finally selected βG-Spray and βG-Gel, 
respectively (Table 1). A βG-concentration-range between 1.6 and 2.4 % 
(w/w) was investigated. As expected, the lowest concentration of βG 
(1.6–1.8 % (w/w)) gave weaker and less versatile gels that would be 
more prone to slip off the application site/wound. CMC was the selected 
thickening agent and glycerol was applied as a humectant in all spray 
formulations as in the commercially available βG-Gel. However, since a 
less viscous formulation was targeted to make the spray formulation 
sprayable, a CMC with a lower molecular weight (MW 250,000) was 
used compared to in the βG-Gel (MW 725,000). This is likely why a 
higher concentration of CMC was found to be desirable for the βG-Spray; 
2.5 % (w/w) as compared to 1.8 % (w/w) in the βG-Gel (Table 2). A CMC 
concentration of 4.0 % (w/w) was applied for the NoβG-Spray (Table 2). 
This higher CMC concentration was selected since βG was lacking in this 
carrier control spray formulation, and more CMC was needed to 
compensate for the missing viscosity contribution from βG (Table 3). A 
glycerol concentration range from zero to 20 % (w/w) was investigated. 
Glycerol seemed to increase the melting point (Table 1), and considering 
that the glycerol concentration in the βG-Gel is 20 % (w/w) and a pre-
viously tested spray formulation with the same active ingredient con-
tained 10 % (w/w) glycerol [33], a similar concentration range would be 
preferable to compare the results. Formulation 10 (Table 1) had a 
glycerol content of 10 % (w/w), and the same βG-concentrations to the 
βG-Gel. This similarity, as well as the seen favorable rheological features 
of Formulation 10 with a relatively high yield stress point of 93.5 Pa (SD 
± 5.5), and a melting point very similar to the βG-Gel formulation, made 
Formulation 10 the choice for further studies as our βG-Spray candidate. 
The compositions of the selected Spray candidate, the carrier control as 
well as for the βG-Gel, are given in Table 2. 
The selected spray formulations (Table 2) were tested for their 
rheological stability over a period of 56 weeks (Table 3). The NoβG- 
Spray formulation had a G′ < G′′ at every time point, and thus classified 
as a viscous solution rather than a gel, with no yield point. For the same 
formulation, the storage modulus was lower than the loss modulus, and 
subsequently the phase angle was over 45◦, indicating fluid behaviour 
[45,46]. The phase angle of the NoβG-Spray formulation was 84.4◦ (SD 
± 1.12) at week one and did not change (p greater than 0.05) at any 
sampling point throughout the 56 weeks test period (Table 3). The 
measured decrease in phase angle for the βG-Spray formulations shows 
an increase in the elastic modulus, indicating a strengthening of the gel 
structure. This observation was supported by the increase in yield stress 
during storage (Table 3). The increased yield stress indicates that more 
force was needed for the gel to obtain a liquid behavior. Despite the 
observed increased gel stiffness and increased energy needed to break 
the gel during storage, both formulations were confirmed to be spray-
able after 56 weeks, using both the 45 and the 140 µL per dose actuators. 
In conclusion, the NoβG-Spray and the βG-Spray, were judged stable and 
appropriate formulations for use in further studies as the spray dressing 
candidate and a carrier control, respectively. 
3.2. Fluid donation and absorption 
The three formulations; βG-Spray, NoβG-Spray and βG-Gel, were 
found to have similar fluid donation capacities (i.e., 9.2 % ± 0.5 [SD], 
6.5 % ± 1.0 [SD] and 8.7 % ± 0.4 [SD], respectively), whereas the βG- 
Gel formulation had more than twice the absorption capacity as 
compared to the spray formulations (Fig. 4). 
3.3. In vitro cytotoxicity 
The in vitro toxicity of the formulations was tested at three different 
concentrations (1, 10, 100 µg/mL). As shown in Fig. 5, only the median 
concentration of the βG-Spray induced a moderate cell toxicity with a 
survival of approx. 86%. However, no toxicity was seen in any of the 
other formulations at any concentrations. This also included the NoβG- 
Spray formulation, with the higher CMC (Table 2). Thus, no dose 
dependent toxicity was observed for any of the formulations in the in 
vitro toxicity study. 
3.4. In vivo wound healing 
3.4.1. Macroscopic analysis 
The impact of the three formulations on wound closure was inves-
tigated in full-thickness excisional wounds. These wounds were created 
in the dorsal flank skin of healing impaired diabetic db/db mice. 
To assess the wound healing process, scaled digital photographs of 
each wound were taken at each assessment point, and the overall wound 
closure (% of original wound area remaining with time), as well as the 
contributions of contraction and re-epithelialization were calculated 
from these images (Fig. 6). Representative examples showing the closure 
of wounds in each treatment group over time are given in Appendix 1, 
Supplementary Fig. S2. 
As shown in Fig. 6, the closure of wounds over the course of the study 
was investigated and compared for the groups in receipt of: five different 
treatments; the investigated βG-spray formulation (βG-Spray), the car-
rier control spray formulation (NoβG-Spray); a commercial product (βG- 
Gel); a positive control (PDGF-BB + TGF-α) and a negative control 
Table 2 
Composition of the formulations selected for further testing.  
Formulation βG CMC Glycerol H2O 
(%, w/w) (%, w/w) (%, w/w) (%, w/w) 
βG-Gel  2.0 1.8b  20.0  76.2 
βG-Spray  2.0 2.5a  10.0  85.5 
NoβG-Spray  – 4.0a  10.0  86.0  
a Medium MW CMC (MW 250,000). 
b High MW CMC (MW 725,000). 
Table 3 
Stability of spray formulations tested over 56 weeks.  
Week βG-Spray NoβG-Spray  
Phase angle 




degree δ (̊) 
Yield point 
(Pa) 
1 9.41 ± 0.52 107.4 ± 4.51 84.4 ± 1.12 NA 
2 8.56 ± 0.31 116.4 ± 3.73 85.3 ± 0.26 NA 
6 8.39 ± 0.56 116.6 ± 4.90 85.3 ± 0.03 NA 
14 7.95 ± 0.18a 124.9 ±
2.07a 
84.9 ± 0.41 NA 
26 8.40 ± 0.35a 123.8 ±
4.87a 
84.9 ± 0.37 NA 
56 7.14 ± 0.15a 126.0 ±
3.51a 
83.3 ± 1.73 NA  
a p < 0.05 vs week 1. 
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(water for injection). During the study timeframe, all treatments resul-
ted in significantly accelerated wound closure (p < 0.05), when 
compared to the negative water treatment control. This was most 
apparent and sustained with the positive control, with significantly 
greater wound closure observed at all assessment points. 
Treatment with the βG-Spray resulted in significantly greater levels 
of closure (p < 0.05) than with the carrier spray alone (NoβG-Spray) on 
post-wounding days 8, 12 and 16. When the βG-Spray treatment was 
compared to the commercially available βG-Gel preparation, very 
similar wound closure profiles were observed (Fig. 6A). Treatment with 
the control spray (NoβG-Spray), which has no βG component, also 
encouraged the wound closure process when compared to negative 
control (water for injection) treatment. 
Wound closure was also considered in terms of its components; 
contraction and re-epithelialization (Fig. 6B). Here, closure by 
contraction was found to be the main closure mechanism for all treat-
ment groups, with improvement in re-epithelialization playing a less 
significant role. Significantly elevated wound contraction (p < 0.05) was 
observed for all treatment groups from day 8 onwards, compared to the 
negative control (Fig. 6B). Compared to positive control, the βG-Gel and 
the βG-Spray treatments resulted in significantly greater contraction 
from day 16 and day 24 and onward, respectively. The level of 
contraction observed with βG-Spray and βG-Gel was indistinguishable 
throughout the study, whereas the βG-Spray treatment gave a signifi-
cantly greater contraction than the carrier spray (NoβG-Spray) on days 
8, 12 and 16 (p < 0.05). When re-epithelialization was considered, 
positive control treated mice displayed the most rapid and most exten-
sive re-epithelialization of all treatment groups, with a peak in re- 
epithelialization of ~ 45 % on post-wounding day 12. Similar to the 
contraction levels, the re-epithelialization from βG-Spray and βG-Gel 
treatments were found to be very similar, and both gave significantly 
greater re-epithelialization (p < 0.05) compared to the NoβG-Spray 
treatment on post-wounding days 8 and 12. 
Animals treated with βG-Spray formulation did not show any signs of 
adverse effects during the experimentation period; wounds healed in a 
similar fashion to that observed for the commercial gel product; βG-Gel. 
3.4.2. Histological analysis 
Our histological investigations showed that the amount of granula-
tion tissue formed within wounds varied between the treatment groups 
Fig. 4. Fluid absorption and donation properties of the sprayable formulation (βG-Spray), the carrier control (NoβG-Spray) and the comparator dressing formulation 
(βG-Gel). n = 5 (% mean, ± SD). 
Fig. 5. Cytotoxicity of the formulations to HaCaT keratinocytes assessed using the MTT-assay. Each formulation (βG-Gel, βG-Spray and NoβG-Spray) was tested at 
three concentrations (1, 10, and 100 µg/mL). Results are given as mean of two independent experiments (% mean, ± SD). Non-treated cells under similar condition 
are considered as 100 % viable and not shown here. 
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(p < 0.05). As shown in Fig. 7A, all treatments resulted in greater 
granulation tissue deposition than the negative control (water for in-
jection). While both βG-Gel and βG-Spray treatments resulted in greater 
mean granulation tissue depths compared to the carrier spray (NoβG- 
Spray), no statistically significant differences were detected between 
these treatments. Interestingly, all treatments other than negative 
(water) control treatment gave rise to greater mean granulation tissue 
depths compared to positive control treatment. This reduced granula-
tion tissue depth in positive control wounds is probably explained by 
increased granulation tissue maturity rather than reduced deposition – 
as granulation tissue compacts as it matures. 
When histological re-epithelialization was considered (Fig. 7B), the 
greatest re-epithelialization was seen in positive control treated wounds 
and the lowest in wounds treated with the negative (water) control (p <
0.05). High levels of re-epithelialization were also observed with βG-Gel 
and βG-Spray; but only the former was found to be significantly greater 
than that in response to negative control treatment (p < 0.05). While 
both βG-Gel and βG-Spray were found to have re-epithelialized to a 
greater extent, neither proved to be significantly greater than that 
observed with the carrier spray (NoβG-Spray). 
Collagen deposition within granulation tissue was found to be 
highest in the group treated with the positive control and lowest in 
negative control treated wounds, in both the central wound and mar-
ginal regions. This proved to be statistically significant in the central 
wound region only (p < 0.05). While both βG-Gel and βG-Spray treat-
ments resulted in greater mean collagen deposition values than the 
NoβG-Spray and negative control treatments, no statistically significant 
differences were detected (Fig. 7C). 
4. Discussion 
Hydrogels are recommended for use in the treatment of chronic 
wounds, as they are able to cleanse wounds by rehydrating dead tissues 
and assist in autolytic debridement [5]. Furthermore, hydrogels can 
reduce perceived pain and promote re-epithelialization by providing a 
moist wound healing environment [34]. Clinical studies have suggested 
that βG-hydrogels promote the healing of chronic wounds by two 
mechanisms; by i) the abeforementioned favorable environmental ef-
fects of the hydrogel in the wound, and ii) the βG components activation 
of macrophages – which are known to orchestrate the wound healing 
process [26]. As far as we know, spray-application of βG-hydrogels 
represents a novel treatment of chronic wounds. The ease by which 
Fig. 6. Impact of treatment on wound closure over the 24-day study period. A) Remaining open wound area (%) with time, B) Wound closure (%) and the relative 
contribution of contraction and re-epithelialization to total wound closure. Positive control (10 µg PDGF-BB and 1 µg TGF-α). (% mean, ± SEM) (n = 10). 
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spray-formulations can be applied makes the spray format suitable for 
administration by both medical professionals and patients themselves, 
and particularly interesting for treatment of large or hard to access 
wounds [30,47]. Thus, a spray formulation will offer advantages in the 
treatment of certain wounds as compared to the currently commercially 
available βG-Gel, a semisolid hydrogel usually spread on the wound 
surface with a gloved finger. 
For a hydrogel to be both sprayable and retained at the wound sur-
face, it must possess certain rheological characteristics. Thus, a multi- 
factorial design matrix was applied for the screening study (Table 1), 
with preselected concentrations ranges for the three ingredients. The 
ingredients included in the spray formulations; βG, CMC and glycerol, 
were selected based on the composition of a marketed βG hydrogel 
product (Woulgan® Gel) – referred to as βG-Gel in this article. The active 
ingredient, βG, is a water-soluble β-1,3/1,6-glucan isolated from baker’s 
yeast (Saccharomyces cerevisiae). βG was provided in the form of a 
sterile hydrogel, containing 2.5 % (w/w) βG in water [38,48]. βG has an 
weight-average MW of about 7 × 105 g/mol, with a wide size distribu-
tion, and forms a tertiary triple-helix structure in an aqueous solution 
[49]. This higher order of structure is thought to be vital to elicit 
immunological activity, but the binding of β-glucans to the immune 
receptors is still not fully understood [50]. In this work, βG at concen-
trations ranging from 1.6 to 2.4 % (w/w) was evaluated. In a previous 
study, 1.0 % (w/w) βG was assessed to be the lowest concentration 
necessary for optimal wound healing [33]; and 2.0 % (w/w) βG in the 
βG-Gel, has been shown to be effective in the clinical setting [23,26]. 
The commercial βG-Gel contains a high viscosity 725 kDa CMC as a 
thickening agent; but, as we aimed to develop a less viscous, sprayable 
product, a CMC with a MW of 250 kDa was selected. CMC is a highly 
water-soluble anionic polysaccharide of ether cellulose, with a long 
tradition of use in topical formulations [5,51,52]. The swelling and 
mucoadhesive properties of CMC make it an excellent ingredient for 
wound dressings. After some preliminary experimentation (results not 
shown), a CMC concentration range between 0.5 and 2.5 % (w/w) were 
investigated in this study. The third ingredient, glycerol, was added as a 
humectant in a concentration range from zero to 20 % (w/w). This range 
was chosen since the commercially marketed βG-Gel contains 20 % (w/ 
w) glycerol. All the 15 spray formulations were proven to be sprayable 
with the selected container and pump system (the nozzle Comfort® 
spray system). Resistance to friction between the wound and the sec-
ondary dressing desire a relatively high yield stress [15]. As seen in 
Table 1, a yield stress point of 93.5 Pa (SD ± 5.5) was obtained for 
Formulation 10, corresponding to the finally selected βG-Spray. This 
higher yield stress is thought to be due to the inclusion of the high(est) 
CMC-concentration of 2.5 % (w/w) in this formulation. However, all 
ingredients seem to increase the yield stress, and βG even more than 
CMC. Although Formulation 14 (Table 1), with 15 % (w/w) glycerol, 2.0 
% (w/w) CMC and 2.2 % (w/w) βG, was the spray formulation with the 
overall highest yield stress of 97.2 (±9.6), Formulations 10 with a yield 
stress of 93.5 Pa (SD ± 5.5) was preferred formulation for further testing, 
because i) this difference in yield stress was not statistically significant, 
and ii) Formulations 10 had the same concentrations of βG as the as the 
commercial product, βG-Gel. The melting temperature of the formula-
tions was determined using the oscillation temperature ramp protocol 
(Table 1). All formulations had a melting temperature higher than 
normal skin temperature (33 ◦C). Formulation that lacked glycerol 
(Formulation 7) had the lowest melting temperature recorded (34.6 ◦C), 
and formulations containing only 5% glycerol had a melting point ≤
39.6 ◦C (Table 1). Thus, glycerol increased the melting temperature of 
these hydrogels. This is in accordance with other publications where 
glycerol has shown to stabilise the polymer gel network through the 
formation of hydrogen bonds [53]. The βG-Spray and the βG-Gel were 
found to have a melting point of 39.8 ◦C (SD ± 0.1) and 40.1 ◦C (SD ±
0.2), respectively. This indicates that neither formulation would melt 
when applied to the wounds. 
As shown in Table 2, 4.0 % (w/w) CMC was selected for the NoβG- 
Spray, the carrier control applied in the in vivo studies. Although the 
total polymer concentration (w/w) is similar to that of the βG-Spray 
formulation, the NoβG-Spray formulation had a lover viscosity than βG- 
Spray (Table 3). Thus, the active ingredient, βG, is forming a more rigid 
polymer network than CMC with the applied (MW = 250,000). This 
means that the carrier control, NoβG-Spray, did not only lack the active 
ingredient, βG, but also displayed less desirable rheological features as a 
wound healing product. 
A long shelf life, preferably at room temperature, is always aimed for 
when developing new medical products. In this study, the stability was 
assessed for 56 weeks, by recording the rheological propertied of the two 
selected spray formulations (the βG-Spray and NoβG-Spray) (Table 3). 
Rheological changes of the product will not only reflect chemical and 
physical degradation of the product, but might also change the dressings 
ability to be retained at the wound surface, which is critical for the 
dressing to assert its effect [15]. As shown in Table 3, a delayed onset of 
the 3D gel-network formation by the βG polymers was observed from the 
yield point assessments. The phase angles of the βG-Spray formulation 
did not change significantly between week 1 and week 2 (p greater than 
0.05). The significant reduction in phase angle and increase in yield 
Fig. 7. Impact of treatment on post-wounding day 24, with regards to A) 
granulation tissue depth, B) ‘histological’ re-epithelialization and C) collagen 
deposition in granulation tissue both in margins and central wound. Positive 
control (10 µg PDGF-BB and 1 µg TGF-α). (mean, ± SEM) (n = 4). 
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point after 14 weeks of storage suggests strengthening of the βG-polymer 
network. Since the sprayability might be affected by gel stiffness, the 
sprayability was retested and confirmed for both spray-formulations 
after 56 weeks of storage. Thus, we concluded that both the βG-Spray 
and NoβG-Spray formulations were stable over 56 weeks, in terms of 
both sprayability and gel strength. Further characterisation and testing 
were therefore encouraged for both formulations, despite the liquid 
behavior of the NoβG-Spray. 
A moist wound environment is considered to be the best environ-
ment for wound healing to occur [5]. Maintaining a favorable moisture 
balance, and avoiding a too wet or dry environment, is essential to 
promote wound debridement and provide a matrix for skin regeneration 
[15]. Hydrogel dressings should therefore be able to donate moisture to 
dry wounds and absorb excess moisture under exudative conditions. 
Since dry to low exuding wounds were the target wound type for the 
spray format, the similar fluid donation capacity and the lower fluid 
absorption capacity of the βG-Spray formulation as compared to the βG- 
Gel (Fig. 4), was considered a positive outcome. The higher absorption 
capacity of the βG-Gel formulation, as compared to the βG-Spray 
formulation, supports its use in more highly exuding wounds. This is in 
accordance with recommended use of this commercial βG-Gel, which is 
indicated for low to moderately exuding chronic wounds [26]. All three 
formulations in this study showed good buffering capacity for moisture 
handling in the wound bed, with a capacity to both absorb and donate 
more than 6 % (w/w) liquid/wound exudate. The ability to donate fluid 
to wounds helps with autolytic debridement; whereas the ability to 
absorb wound exudate and debride slough helps healthy tissue to re- 
epithelialize [14]. Providing too much moisture to wounds can lead to 
maceration of peri-wound tissue which can extend healing time [14]. 
The importance of selecting a suitable thickening agent to formulate a 
hydrogel for wound healing applications, was highlighted by previous 
work performed by our group [33]. In this study, Carbopol (Lubrizol, 
USA) was selected as the thickening agent. Fluid affinity investigations 
of these Carbopol formulations showed a low absorptive capacity (0.5 % 
(w/w)) combined with a high fluid donation capability (17 % (w/w)). As 
a consequence, excessive hydration, tissue maceration and impaired 
wound closure were observed. The βG-Gel formulation and the βG-Spray 
formulations differ with regards to glycerol concentrations, with 20 % 
(w/w) and 10 % (w/w), respectively. This might contribute to the higher 
absorption of fluid by the βG-Gel, as glycerol have been reported to 
absorb three times its own weight in water [54]. Although being a hu-
mectant, glycerol is also hygroscopic and a viscous liquid that acts as a 
wetting agent when swelling the polymers into a hydrogel network. The 
most likely explanation for the difference in absorption ability between 
these two formulations (Fig. 4), is therefore the different CMCs applied. 
It appears that the high molecular mass CMC applied in the βG-Gel 
formulation forms a hydrogel structure with a higher absorption ca-
pacity than the medium molecular mass CMC applied in the sprayable 
formulations. The two spray formulations investigated, βG-Spray and 
NoβG-Spray, showed a very similar fluid affinity profile. Thus, the 
polymer network and interaction of βG and CMC seem to have similar 
absorption and donation features as CMC alone when the medium mo-
lecular mass CMC is used. The dry polymer mass in the βG-Spray was 4.5 
% (w/w), whereas the NoβG-Spray formulation containing 4.0 % CMC 
(Table 2). Increasing the polymer concentration of the NoβG-Spray 
formulation, may therefore have made the fluid affinity profiles even 
more similar. However, these results show that all formulations have the 
desired ability to both donate and absorb fluid. 
The biocompatibility of a medical product is essential to ensure its 
safe use in the clinical setting. Keratinocytes play a crucial role in 
epidermal tissue regeneration, and HaCaT cells (a spontaneously 
immortalized, human keratinocyte cell line) therefore provide a useful 
in vitro tool for determining potential cellular toxicity. Toxicity assess-
ments based on the survival of HaCaT cells, usually claim substances are 
‘non– cytotoxic’ with greater than 90 % cell survival, ‘moderately 
cytotoxic’ with 80 to 90 % cell survival, and ‘significantly cytotoxic’ 
with <80 % survival [55]. The MTT assay findings generated in this 
work (Fig. 5) showed that none of the formulations tested (βG-Gel, βG- 
Spray or NoβG-spray) displayed any significant cytotoxicity at the 
highest concentration tested. The lack of cytotoxicity to HaCaT cells, 
with NoβG-Spray at any of the tested concentrations (Fig. 5), correlates 
well with other studies that have investigated CMC and βG [56,57]. 
These positive biocompatibility findings were confirmed by the 
apparent lack of cellular toxicity or other adverse effects in subsequent 
diabetic mouse wound healing studies. 
The diabetic db/db mouse delayed wound healing model, also pre-
viously described by our group [27,33], is a useful tool in the pre-clinical 
evaluation of wound healing therapies [58]. Using this model, βG-Spray 
was found to promote wound healing at both the macroscopic and his-
tological levels, to a level largely similar to that of the commercial 
comparator βG-Gel. At the macroscopic level, both βG formulations were 
found to give rise to significant improvements in overall wound closure 
and its components contraction and re-epithelialization, when 
compared to the carrier control formulation NoβG-Spray. 
The wound healing rates in both the βG-Spray and the βG-Gel 
treatment groups were observed to decrease around day 12 post- 
wounding (Fig. 6A). As these formulations were only administered on 
day 0, 2, 4, 6 and 8 post wounding, it is possible that the healing rate 
could have been maintained, if these treatments had continued to be 
applied after day 12. In a study by Berdal and co-workers, the authors 
reported a dose frequency dependency of the β-glucan used on wound 
closure rate, favouring a more frequent administration of β-glucan for 
increased wound closure [59]. Consequently, the impact of longer-term 
treatments should be investigated closer in future optimisation of these 
formulations. 
Interestingly, the vehicle formulation (NoβG-Spray) also gave rise to 
significant improvements in the overall wound closure, and promoted 
both wound contraction and granulation tissue formation relative to the 
negative control treatment (water for injection). This may be explained 
by the fluid handling properties of CMC, and/or possibly also by CMC’s 
overall favorable effect on the wound healing process [36,51]. CMC is 
used in numerous commercially available wound treatments and has 
also previously been shown to increase the rate of wound healing 
compared to control treatment. Fluid handling of the applied formula-
tion seems to be very important, taking into consideration the poor in 
vitro performance of the previously tested Carbopol-based spray for-
mulations investigated [33], as well as the liquid behaviour of the NoβG- 
Spray formulation (Table 3). It is thus suggested that the observed 
adverse effects of the Carbopol-containing formulation noted in our 
previous work [33], was a consequence of an inadequate fluid absorp-
tion and extensive fluid donation. If this is the case, the choice of 
thickening agent seem to be of paramount importance for its clinical 
success in wound healing. The NoβG-Spray, although lacking the active 
ingredient, enabled formation of a viscous solution, which can exhibit 
beneficial physical protection, and an adhesion-free cover of the sensi-
tive wound tissue, acting on improved wound healing. 
When the impact of treatment was considered at the histological 
level (Fig. 7), both βG formulations gave rise to improvement in wound 
healing, but this improvment was non-significant relative to the NoβG- 
Spray treatment. Actually, all the hydrogel formulations were found to 
encourage granulation tissue formation, re-epithelization and collagen 
deposition in the central wound relative to the water-control (p < 0.05). 
As noted previously, all three hydrogel formulations (βG-Gel, βG-Spray 
and NoβG-Spray) acted to promote wound closure primarily by pro-
moting wound contraction rather than re-epithelialisation, an observa-
tion that parallels previous βG work by our group [27,33]. As 
contraction is driven by the compaction of granulation tissue this may 
suggest that these formulations act to encourage wound closure by 
promoting the formation, and/or quality, of granulation tissue. Granu-
lation tissue formation is known to be orchestrated by macrophages, and 
β-glucans are immunological response modifiers, that can activate 
wound macrophages, which may explain the beneficial effects of 
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β-glucans noted in this study, in our previous work, and work by others 
[23,28,37,60–63]. Since the histology was obtained at the final day of 
the in vivo study, a very pronounced observed effect from β-glucan could 
not be anticipated, taking into account the macroscopic analysis at the 
same time point (Fig. 6). Thus, the histology findings fully support the 
reported macroscopic analysis in this in vivo wound healing study. 
The data generated from this in vivo study clearly demonstrates the 
beneficial effects of a sprayable βG-supplemented hydrogel on the 
mammalian wound healing process, and highlights its significant po-
tential as a treatment for chronic wounds. 
5. Conclusion 
A sprayable hydrogel formulation comprising the immunomodula-
tory soluble β-1,3/1,6-glucan, isolated from baker’s yeast (Saccharo-
myces cerevisiae), was successfully prepared. The new spray formulation 
showed equivalent wound closure time as the commercially available 
semisolid hydrogel formulations. Since the spray is designed for multiple 
applications particularly targeting bigger and dryer wounds than the 
current available semisolid βG-formulations, this new βG-Spray will 
expand βG’s clinical use, as the spray format will be beneficial for 
different patient groups and wounds. 
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